Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
Juan Bautista Blaquier, Andrés F. Cardona, Gonzalo Recondo
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Dynamic regulation of RAS and RAS signaling
Walter Kölch, Dénes Berta, Edina Rosta
Biochemical Journal (2023) Vol. 480, Iss. 1, pp. 1-23
Open Access | Times Cited: 53
Tumor heterogeneity: preclinical models, emerging technologies, and future applications
Marco Proietto, Martina Crippa, C. Damiani, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 49
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Xinyuan Tong, Ayushi Patel, Eejung Kim, et al.
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 413-428.e7
Open Access | Times Cited: 33
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Firas Batrash, Mahmoud Kutmah, Jun Zhang
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Lee Jy, Richie R. Bhandare, Sai H. S. Boddu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116275-116275
Open Access | Times Cited: 8
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Simon Manuel Tria, Matthew Burge, Vicki Whitehall
Cancers (2023) Vol. 15, Iss. 8, pp. 2375-2375
Open Access | Times Cited: 20
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
Victor Hugo Fonseca de Jesus, Maria Cecília Mathias-Machado, João Paulo Fogacci de Farias, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5015-5015
Open Access | Times Cited: 17
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration
Jason G. Kettle, Sharan K. Bagal, Derek Barratt, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 9147-9160
Closed Access | Times Cited: 16
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance
Jameela Lokhandwala, Tracess Smalley, Timothy H. Tran
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
Phaedra C. Ghazi, Kayla O’Toole, Sanjana Srinivas Boggaram, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 4
Could Drug Delivery Systems Be Enhancers for Therapy against KRAS-driven Cancers?
Ramil Khusnutdinov
Reviews and Advances in Chemistry (2025)
Closed Access
First molecules to reactivate RASG12V GTPase activity
Aneta Włodarczyk, Cezary Tręda, Marcin Pacholczyk, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future
Peiliang Dong, Jiating Ni, Xinyue Zheng, et al.
European Journal of Pharmacology (2025), pp. 177428-177428
Closed Access
Precision peptide disruptors: The next generation of targeted therapeutics in oncology
Bria O'Gorman, Sean F. Cooke, Connor M. Blair
Cellular Signalling (2025), pp. 111783-111783
Open Access
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
Francesca Aroldi, Elena Élez, Thierry André, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
Nastaran Karimi, Seyed Javad Moghaddam
Cells (2023) Vol. 12, Iss. 5, pp. 749-749
Open Access | Times Cited: 12
Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer
Phaedra C. Ghazi, Kayla O’Toole, Sanjana Srinivas Boggaram, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 4
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4164-4164
Open Access | Times Cited: 17
The Role and Therapeutic Implications of Inflammation in the Pathogenesis of Brain Arteriovenous Malformations
Ashley R. Ricciardelli, Ariadna Robledo, Jason E. Fish, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 2876-2876
Open Access | Times Cited: 10
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
Kenji Morimoto, Tadaaki Yamada, Soichi Hirai, et al.
Cancer Letters (2024) Vol. 587, pp. 216692-216692
Open Access | Times Cited: 3
Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
Robert J. Norgard, Pratha Budhani, Sarah A. O’Brien, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 6, pp. 1548-1560
Open Access | Times Cited: 3
CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
Asa P. Y. Lau, Sharon S. Khavkine Binstock, Kelsie L. Thu
Cancers (2023) Vol. 15, Iss. 21, pp. 5229-5229
Open Access | Times Cited: 7
Nanotechnology-assisted intracellular delivery of antibody as a precision therapy approach for KRAS-driven tumors
Ana M. López-Estévez, Lucía Sanjurjo, Ángela Turrero, et al.
Journal of Controlled Release (2024) Vol. 373, pp. 277-292
Open Access | Times Cited: 2
Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96
Randa Mahran, Jonas N. Kapp, Salla Valtonen, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 10, pp. 2152-2164
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top